EE266 Societal Economic Impact of Treatment with Adjuvant Osimertinib in Patients with Early-Stage (IB-IIIA) EGFRm NSCLC

Saved in:
Bibliographic Details
Published in:Value in health 2023-06, Vol.26 (6), p.S107-S107
Main Authors: Bracke, B., Flint, I., McCrea, C., Freigofaite, D., Hu, Y., Verhoek, A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2023.03.567